Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France
Didier Debieuvre , Isabelle Monnet , Olivier Bylicki , Sophie Schneider , Francois Goupil , Benoit Godbert , Christine Dussopt , Herve Pegliasco , Laurent Portel , Reda Chikouche , Philippe Masson , Mohamad Jaafar , Clothilde Marty , Fethi EL Khanjari , Julie Obert , Marjorie Picaud , Anne Sophie Bravard , Herve Le Floch , Alexia Letierce , Hugues Morel
Background: Each decade since 2000, the French College of General Hospital Pulmonologists (CPHG) conducts the KBP study, a real-life nationwide prospective multicenter study on LC in non-academic public hospital (NPH). Here, we report the two-year survival (2-y) rate among the 2020 cohort and the comparisons with the 2000 and 2010 cohorts. Methods: Collection of all consecutive diagnosed LC, all stage and all histology, between 01/01 and 12/31 in NPH pulmonology or oncology units in 2000, 2010 and 2020 with the same methodology. A Scientific Committee controlled inclusion exhaustivity and quality in each center. Survival rates were calculated using the Kaplan-Meier method and risk factors were assessed using Cox models. Results: 8,999 patients were included in 82 centers in 2020. The 2-y survival rate was 40.3%, the median overall survival was 15.3 months. Compared to 2000, mortality rates at 2 years decreased significantly (-19.1%), while early (1 month and 3 months) mortality remains similar. Survival improved in 20 years whatever histologic types (Table). Factors associated with 2-y survival were sex (36.1% vs 48.1% respectively for male and female respectively, significantly increased over 20 years: + 15.3% for M and + 24.5% for F), high age (>80 y-o), poor ECOG status (3 or 4) and advanced disease. As expected in 2020, TNM stage was still determining for 2-year mortality, 15.2 [12.6-17.7] stage I vs 75.6 [74.4-76.8] stage IV. In 2020 the Covid-19 infection (n=283) impacted the survival (HR = 4.02 95%CI [3.33-4.86]) on multivariate analysis adjusted to age, sex, tobacco consumption, histology, ECOG status, TNM stage. Conclusions: These results confirmed the major improvement in the last two decades for LC. 5-years survival will provide us more enlightenment.
Overall mortality | Months | 2000 | 2010 | 2020 |
---|---|---|---|---|
1 | 10.4 [9.6 - 11.2] | 9.8 [9.1 - 10.4] | 8.2 [7.7 - 8.8] | |
3 | 24.6 [23.4 - 25.7] | 23.3 [22.3 - 24.3] | 20.2 [19.4 - 21.0] | |
12 | 60.1 [58.8 - 61.4] | 56.9 [55.7 - 58.0] | 44.5 [43.4 - 45.5] | |
24 | 78.8 [77.7 - 79.8] | 74.2 [73.2 - 75.3] | 59.7 [58.7 - 60.8] | |
Median survival time (months) | 8.8 [8.4 - 9.1] | 9.7 [9.4 - 10.1] | 15.3 [14.6-16.1] | |
Mortality / histology | Months | 2000 | 2010 | 2020 |
SCLC | 24 | 88.3 [86.0 - 90.3] | 86.4 [84.0 - 88.4] | 80.6 [78.0 - 82.9] |
Squamous | 24 | 75.6 [73.7 - 77.4] | 70.9 [68.8 - 73.0] | 61.5 [59.1 - 63.6] |
Non-SCLC, non-squamous | 24 | 76.5 [74.3 - 78.5] | 72.3 [70.7 - 73.9] | 54.4 [52.9 - 55.9] |
*Preliminary results with 1291 missing data at Month 24 – Update will be available for the congress.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Kathleen Kennedy
2024 ASCO Annual Meeting
First Author: Edward Christopher Christopher Dee
2024 ASCO Annual Meeting
First Author: Samia Asif
2023 ASCO Annual Meeting
First Author: Jason S. Agulnik